Russian drugmakers significantly increase number of clinical trials

Russian pharmaceutical manufacturers have increased the number of clinical trials that are conducted in the domestic market as part of their efforts of import substitution, The Pharma Letter’s local correspondent reports.

According to the Russian Vedomosti business paper, citing data from the Russian Register of Permits for Clinical Trials (RCTs), the growth in the number of clinical trials was observed in case of most of leading Russian drugmakers.

For example, the R-Pharm has received 21 permits since the beginning of the year, although at the end of nine months of 2022 there were only seven. At Geropharm, the number increased from 4 to 20, while in the case of Pharmstandard it was up from 5 to 11.